Congressional Research Service Reports - 555 Matching Results
Search Results
- The Global Fund to Fight AIDS, Tuberculosis, and Malaria: Issues for Congress and U.S. Contributions from FY2001 to FY2013
- The Global Fund to Fight AIDS, Tuberculosis, and Malaria (Global Fund, or the Fund) was established in 2002 as a public-private partnership that could provide significant financial support for global responses to HIV/AIDS, tuberculosis (TB), and malaria. In November 2011, the Global Fund Board announced that due to inadequate resources from donors, it would cancel its 11th round of funding, but would maintain support for existing activities to avoid disruptions in ongoing services. Global health advocates urge Congress to meet the President's FY2013 request for the Fund in order to support the sustainability of its activities and to encourage continued contributions from other donors. Although Congress has traditionally been a strong supporter of the Fund, several issues may affect congressional views about the Fund in the future, which are discussed in this report.
- Science, Technology, and Medicine: Issues Facing the 106th Congress, First Session
- Science, technology, and medicine is playing an integral part in many of the policy issues that are coming before this Congress. Legislative action in certain areas directly affects the progress of science, technology, and medicine (STM). And advances in those areas can significantly affect broader public policy issues. This issue brief provides an overview of several of those issues and identifies CRS reports that treat them in more depth.
- Tobacco Control: Enforcement and Effectiveness of Federal and State Youth Access Laws
- This report reviews recent efforts to limit youth access to cigarettes through enforcement of federal and state laws prohibiting tobacco sales to minors. Under the federal Synar Amendment, states must conduct compliance checks and enforce their minimum age-of-sale laws or risk losing block grant funds
- Science, Technology, and Medicine: Issues Facing the 105th Congress, First Session
- Science, technology, and medicine are an indisputable part of many of the policy issues that may come before the Congress this coming year. This report provides an overview of several of these issue and identifies CRS publications that treat them in more depth.
- Medicaid Prescription Drug Pricing and Policy
- This report provides an overview of the Medicaid prescription drug pricing and policy.
- U.S. Response to the Global Threat of Tuberculosis: Basic Facts
- This report outlines basic facts related to global tuberculosis (TB), including characteristics of the epidemic and U.S. legislation, programs, funding, and partnerships related to the global response to TB.
- Public Health and Medical Emergency Management: Issues in the 112th Congress
- This report summarizes key issues in domestic public health and medical preparedness and response, and discusses selected federal programs by citing other CRS reports and sources of additional information.
- U.S. and International Health Responses to the Ebola Outbreak in West Africa
- In March 2014, an Ebola Virus Disease (EVD) outbreak was reported in Guinea, West Africa. The outbreak is the first in West Africa and has caused an unprecedented number of cases and deaths. The outbreak is continuing to spread in Guinea, Sierra Leone, and Liberia (the "affected countries"); it has been contained in Nigeria and Senegal, and has been detected in Mali. As of October 22, 2014, more than 10,000 people have contracted EVD, more than half of whom have died. This report focuses on the health impacts of the outbreak and discusses U.S. and international responses to those health challenges.
- Immigration Policies and Issues on Health-Related Grounds for Exclusion
- This report discusses the criteria that foreign nationals must meet before admission to the United States, including the reasons why a foreign national might be denied admission, most particularly on health-related grounds. This report discusses such issues in relation to the recent outbreak of the 2009 H1N1 ("swine flu") virus, and how the outbreak has affected various government agencies, such as the Customs and Border Protection (CBP) agency within the Department of Homeland Security (DHS). This report also discusses efforts to confront and address such issues on a legislative front.
- Federal Taxation of the Drug Industry and Its Effects on New Drug Development
- This report examines the impact of federal taxation on the incentive to invest in new drug development. More specifically, it looks at the provisions in current tax law that affect the performance of the drug industry, compares the industry's federal tax burden with that of other major industries, and assesses the effect of federal taxation on the incentive to invest in new drug development.
- Legal Issues Related to Prescription Drug Sales on the Internet
- This report provides a legal analysis of issues related to prescription drug sales on the Internet, including issues involving online pharmacies and physicians who prescribe medications over the Internet. This report also provides an overview of the various federal and state laws that regulate this field, including laws and regulations covering prescription drugs, controlled substances, doctors, and pharmacies.
- Patient Protection and Mandatory External Review: Amending ERISA's Claims Procedure
- No Description Available.
- Science, Technology, and Medicine: Issues Facing the 106th Congress, Second Session
- No Description Available.
- International Convention Against Doping in Sport: Issues for Congress
- The International Convention Against Doping in Sport seeks to harmonize anti-doping commitments for non-professional sports at the international level. This Convention was adopted by the United Nations Educational, Scientific, and Cultural Organization (UNESCO) in 2005 and entered in force on February 1, 2007. Issues that could arise as the Senate considers the treaty include its relationship to anti-doping regulations in professional sports, potential consequences that non-ratification could pose to the United States, and the legitimacy and effectiveness of current international anti-doping activities.
- Stem Cell Research
- Embryonic stem cells have the ability to develop into virtually any cell in the body, and they may have the potential to treat medical conditions such as diabetes and Parkinson’s disease. In August 2001, President Bush announced that for the first time federal funds would be used to support research on human embryonic stem cells, but funding would be limited to “existing stem cell lines.” The National Institutes of Health (NIH) has established the Human Embryonic Stem Cell Registry, which lists 78 stem cell lines that are eligible for use in federally funded research. However, only 22 embryonic stem cell lines are currently available. Scientists are concerned about the quality, and longevity of these stem cell lines.
- Stem Cell Research
- Embryonic stem cells have the ability to develop into virtually any cell in the body, and may have the potential to treat medical conditions such as diabetes and Parkinson’s disease. In August 2001, President Bush announced that for the first time federal funds would be used to support research on human embryonic stem cells, but funding would be limited to “existing stem cell lines.” The National Institutes of Health (NIH) has established the Human Embryonic Stem Cell Registry, which lists stem cell lines that are eligible for use in federally funded research. Although 78 cell lines are listed, 22 embryonic stem cell lines are currently available. Scientists are concerned about the quality, longevity, and availability of the eligible stem cell lines.
- Stem Cell Research
- Embryonic stem cells have the ability to develop into virtually any cell in the body and they may have the potential to treat medical conditions such as diabetes and Parkinson’s disease. In August 2001, President Bush announced that for the first time federal funds would be used to support research on human embryonic stem cells, but funding would be limited to “existing stem cell lines.”
- Stem Cell Research
- Embryonic stem cells have the ability to develop into virtually any cell in the body, and they may have the potential to treat medical conditions such as diabetes and Parkinson’s disease. In August 2001, President Bush announced that for the first time federal funds would be used to support research on human embryonic stem cells, but funding would be limited to “existing stem cell lines.” The National Institutes of Health (NIH) has established the Human Embryonic Stem Cell Registry, which lists stem cell lines that are eligible for use in federally funded research. Although 78 cell lines are listed, 22 embryonic stem cell lines are currently available. Scientists are concerned about the quality, longevity, and availability of the eligible stem cell lines.
- Gulf War Veterans' Illnesses
- In 1990 and 1991, approximately 697,000 U.S. troops were deployed in the Persian Gulf during Operations Desert Shield and Desert Storm. The United States suffered relatively few casualties during the brief air and ground war against Iraq. Since returning home, however, many veterans have developed illnesses that appear to be related to their military service in the Gulf. Researchers caution that it may be impossible to identify the causes of these illnesses because of the absence of baseline data on the health of military personnel and the lack of reliable exposure data. This report provides concise answers to a series of questions concerning Gulf War veterans' illnesses, based on currently available scientific information.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2004
- No Description Available.
- Compensating Farmers for the Tobacco Settlement
- The legislative proposals designed to reduce smoking, primarily by teenagers, are likely to have negative economic consequences for tobacco growers and tobacco-dependent communities. This report discusses the possibility of some kind of compensation to farmers as part of the settlement package legislation.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2004
- No Description Available.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2005
- No Description Available.
- HIV/AIDS International Programs: Appropriations, FY2003-FY2005
- No Description Available.
- Medicare Endorsed Prescription Drug Discount Card Program
- No Description Available.
- Influenza Vaccine Shortages and Implications
- No Description Available.
- Beneficiary Information and Decision Supports for the Medicare-Endorsed Prescription Drug Discount Card
- On December 8, 2003 the President signed into law the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA, P.L. 108-173). This legislation establishes a Medicare prescription drug benefit, effective January 1, 2006. In the interim, the legislation requires the Department of Health and Human Services (HHS) to establish a temporary program of Medicare-endorsed prescription drug discount cards. This report discusses the objectives and benefits of this legislation.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- Background and Legal Issues Related to Stem Cell Research
- In August 2001, President Bush announced that federal funds, with certain restrictions, may be used to conduct research on human embryonic stem cells. This report explains the limitations on this research, as well as corresponding and related legislation to the issue of embryonic stem cell research, including the Stem Cell Research Enhancement Act of 2005.
- Avian Flu Pandemic: Potential Impact of Trade Disruptions
- Concerns about potential disruptions in U.S. trade flows due to a global health or security crisis are not new. The possibility of an avian flu pandemic with consequences for global trade is a concern that has received attention recently, although some experts believe there is little cause for alarm. This report considers possible trade disruptions, including possible impacts on trade between the United States and countries and regions that have reported avian influenza infections.
- A Brief Summary of the HIPAA Medical Privacy Rule
- This report provides a brief overview of the modified HIPAA Privacy rule, “Standards for the Privacy of Individually Identifiable Health Information” (“privacy rule”) published on August 14, 2002 by the Department of Health and Human Services (HHS).
- A Brief Summary of the Medical Privacy Rule
- This report provides a brief overview of the modified medical privacy rule, “Standards for the Privacy of Individually Identifiable Health Information”(“privacy rule”) published on August 14, 2002 by the Department of Health and Human Services (HHS). The privacy regulation creates a new federal floor of privacy protections while leaving in place more protective state rules or practices. The rule establishes a set of basic consumer protections and a series of regulatory permissions for uses and disclosures of protected health information.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2004
- No Description Available.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2004
- No Description Available.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2004
- No Description Available.
- HIV/AIDS International Programs: Appropriations, FY2002-FY2004
- No Description Available.
- State Laws on Human Cloning
- No Description Available.
- HIV/AIDS International Programs: FY2002 Spending and FY2003 Outlook
- No Description Available.
- HIV/AIDS International Programs: FY2003 Request and FY2002 Spending
- No Description Available.
- HIV/AIDS International Programs: FY2003 Request and FY2002 Spending
- No Description Available.
- A Brief Summary of the Medical Privacy Rule
- On March 27, 2002 the Department of Health and Human Services (HHS) published its proposed changes to the medical privacy regulations issued by the Clinton Administration under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). HHS is accepting comments on the proposed changes until April 26, 2002. This report provides an overview of the final rule for “Standards for the Privacy of Individually Identifiable Health Information” ( “privacy rule”) that went into effect on April 14, 2001, and an overview of the Bush Administration’s proposed changes to the privacy regulation.
- A Brief Summary of the Medical Privacy Rule
- This report provides a brief overview of the recently modified medical privacy rule, “Standards for the Privacy of Individually Identifiable Health Information”(“privacy rule”) published on August 14, 2002 by the Department of Health and Human Services (HHS). The privacy rule went into effect April 14, 2001, with compliance required by April 2003 for most entities. The regulation creates a new federal floor of privacy protections while leaving in place more protective state rules or practices. The rule establishes a set of basic consumer protections and a series of regulatory permissions for uses and disclosures of protected health information.
- Background and Legal Issues Related to Stem Cell Research
- In August 2001, President Bush announced that federal funds, with certain restrictions, may be used to conduct research on human embryonic stem cells. Federal research is limited to “the more than 60” existing stem cell lines that were derived (1) with the informed consent of the donors; (2) from excess embryos created solely for reproductive purposes; and (3) without any financial inducements to the donors. No federal funds may be used for the derivation or use of stem cell lines derived from newly destroyed embryos; the creation of any human embryos for research purposes; or cloning of human embryos for any purposes.
- HIV/AIDS International Programs: FY2002 Spending and FY2003 Outlook
- No Description Available.
- Cancer Research: Selected Federal Spending and Morbidity and Mortality Statistics
- This report shows federal spending at the National Institutes of Health (NIH) for research on selected cancer sites.
- Veterans' Medical Care Appropriations and Funding Process
- The Department of Veterans Affairs (VA) provides benefits to veterans who meet certain eligibility rules. Benefits to veterans range from disability compensation and pensions to hospital and medical care. VA provides these benefits to veterans through three major operating units: the Veterans Health Administration (VHA), the Veterans Benefits Administration (VBA) and the National Cemetery Administration (NCA). VHA is primarily a direct service provider of primary care, specialized care, and related medical and social support services to veterans through an integrated health care system. Veterans are enrolled in priority groups that determine payments for service and nonservice-connected medical conditions. In FY2004, Congress appropriated $28.4 billion for VHA to be spent through an account structure composed of four new accounts: medical services, medical administration, medical facilities, and medical and prosthetic research.
- The Pros and Cons of Allowing the Federal Government to Negotiate Prescription Drug Prices
- The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) expressly forbids the Secretary of Health and Human Services (HHS) from negotiating the price of prescription drugs on behalf of Medicare beneficiaries. This report outlines the arguments for and against allowing the federal government to negotiate prescription drug prices on behalf of Medicare beneficiaries. This report will be updated, as needed.
- Summary and Comparison of the Major Agricultural Provisions of the Tobacco Settlement Policy Proposals
- No Description Available.
- Biotechnology: Commercialization of Academic Research
- This report provides an overview of the commercialization of academic research h in the field of biotechnology. It offers a brief definition, background and policy analysis, as well as legislation and hearings regarding the topic.